Instrument Inactif

Autres langues Endonovo Therapeutics, Inc. Other OTC

Actions

ENDV

US29272H3003

Recherche biotechnologique et médicale

Autres langues

28/03/24	Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
04/03/24	Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
29/12/23	Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
04/12/23	Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
12/10/23	Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval
12/10/23	Endonovo's SofPulse® Secures Taiwan FDA Approval
22/08/23	Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
22/08/23	Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
21/08/23	Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
08/08/23	Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
22/06/23	New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc.
07/06/23	Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division
07/06/23	Endonovo Pending Agreement to Develop Telehealth Division
22/05/23	Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
02/05/23	Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration
02/05/23	Endonovo Launches SofPulse® into the Veterans Administration
25/04/23	Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
25/04/23	Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment
17/04/23	ENDONOVO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)
17/04/23	Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
17/04/23	Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
13/04/23	Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman
10/04/23	Endonovo Announces Partnership with Santana Lead Singer Andy Vargas
29/03/23	Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company
29/03/23	ENDONOVO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)